Tokyo Tape
Sign in
← SymBio Pharmaceuticals

Annual report

4582.TEDINET S100QFOG
Period2022-01-01 → 2022-12-31
Filed2023-03-23
StandardJapan GAAP
ConsolidatedYes
Data checks17 of 17 passed

Amended by S100QG6E (2023-03-24).

Key figures · 100
MetricValuePeriodScopeSource row
Revenue¥10.0bn2022-01-01 → 2022-12-31Cons.Net sales
Operating income¥2.0bn2022-01-01 → 2022-12-31Cons.Operating income
Ordinary income¥2.0bn2022-01-01 → 2022-12-31Cons.Ordinary income
Profit before tax¥2.1bn2022-01-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)¥1.2bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income¥1.2bn2022-01-01 → 2022-12-31Cons.Profit loss
Total assets¥10.4bnat 2022-12-31Cons.Assets
Total liabilities¥1.9bnat 2022-12-31Cons.Liabilities
Net assets / equity¥8.5bnat 2022-12-31Cons.Net assets
Net assets / equity¥6.7bnat 2021-12-31Cons.Net assets
Cash and deposits¥6.3bnat 2022-12-31Cons.Cash and deposits
Cash & equivalents¥6.3bnat 2022-12-31Cons.Cash and cash equivalents
Cash & equivalents¥3.9bnat 2021-12-31Cons.Cash and cash equivalents
Operating cash flow¥1.6bn2022-01-01 → 2022-12-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥47m2022-01-01 → 2022-12-31Cons.Net cash provided by used in investment activities
Financing cash flow¥628m2022-01-01 → 2022-12-31Cons.Net cash provided by used in financing activities
EPS (basic)¥30.22022-01-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥29.772022-01-01 → 2022-12-31Cons.Diluted earnings per share (5-year summary)
Net assets per share¥204.83at 2022-12-31Cons.Net assets per share (5-year summary)
Equity ratio77.6%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
ROE14.6%2022-01-01 → 2022-12-31Cons.Rate of return on equity (5-year summary)
Employees122at 2022-12-31Cons.Number of employees
Revenue¥10.0bn2022-01-01 → 2022-12-31StandaloneNet sales
Revenue¥8.3bn2021-01-01 → 2021-12-31StandaloneNet sales
Revenue¥3.0bn2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Revenue¥2.8bn2019-01-01 → 2019-12-31dStandaloneNet sales (5-year summary)
Revenue¥3.8bn2018-01-01 → 2018-12-31dStandaloneNet sales (5-year summary)
Operating income¥2.0bn2022-01-01 → 2022-12-31StandaloneOperating income
Operating income¥1.0bn2021-01-01 → 2021-12-31StandaloneOperating income
Ordinary income¥2.0bn2022-01-01 → 2022-12-31StandaloneOrdinary income
Ordinary income¥1.0bn2021-01-01 → 2021-12-31StandaloneOrdinary income
Ordinary income−¥4.6bn2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥4.4bn2019-01-01 → 2019-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥2.7bn2018-01-01 → 2018-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥2.1bn2022-01-01 → 2022-12-31StandaloneIncome before income taxes
Profit before tax¥1.0bn2021-01-01 → 2021-12-31StandaloneIncome before income taxes
Net income¥1.2bn2022-01-01 → 2022-12-31StandaloneProfit loss
Net income¥2.0bn2021-01-01 → 2021-12-31StandaloneProfit loss
Net income−¥4.1bn2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Net income−¥4.4bn2019-01-01 → 2019-12-31dStandaloneNet income loss (5-year summary)
Net income−¥2.8bn2018-01-01 → 2018-12-31dStandaloneNet income loss (5-year summary)
Total assets¥10.4bnat 2022-12-31StandaloneAssets
Total assets¥8.5bnat 2021-12-31StandaloneAssets
Total assets¥6.3bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total assets¥5.3bnat 2019-12-31dStandaloneTotal assets (5-year summary)
Total assets¥6.2bnat 2018-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥1.9bnat 2022-12-31StandaloneLiabilities
Total liabilities¥1.7bnat 2021-12-31StandaloneLiabilities
Net assets / equity¥8.5bnat 2022-12-31StandaloneNet assets
Net assets / equity¥6.7bnat 2021-12-31StandaloneNet assets
Net assets / equity¥4.7bnat 2020-12-31dStandaloneNet assets
Net assets / equity¥4.4bnat 2019-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥4.9bnat 2018-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥6.3bnat 2022-12-31StandaloneCash and deposits
Cash and deposits¥3.9bnat 2021-12-31StandaloneCash and deposits
Cash & equivalents¥3.9bnat 2021-12-31StandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥3.8bnat 2020-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥3.9bnat 2019-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥4.8bnat 2018-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow¥140m2021-01-01 → 2021-12-31StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥4.1bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥4.4bn2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥2.3bn2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥71m2021-01-01 → 2021-12-31StandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥160m2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥216m2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥26m2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow−¥72m2021-01-01 → 2021-12-31StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥4.2bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥3.7bn2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥4.3bn2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥30.372022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥53.042021-01-01 → 2021-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-124.132020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-189.032019-01-01 → 2019-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-165.542018-01-01 → 2018-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥29.952022-01-01 → 2022-12-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥52.322021-01-01 → 2021-12-31StandaloneDiluted earnings per share (5-year summary)
Net assets per share¥204.95at 2022-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥162.26at 2021-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥105.76at 2020-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥143.07at 2019-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥212.23at 2018-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio77.8%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio73.7%at 2021-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio64.3%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio71.7%at 2019-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio70.1%at 2018-12-31dStandaloneEquity to asset ratio (5-year summary)
ROE16.6%2022-01-01 → 2022-12-31StandaloneRate of return on equity (5-year summary)
ROE39.6%2021-01-01 → 2021-12-31StandaloneRate of return on equity (5-year summary)
Shares issued39,603,606at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued38,457,206at 2021-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued38,202,956at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued26,437,681at 2019-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued83,398,924at 2018-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees118at 2022-12-31StandaloneNumber of employees
Employees141at 2021-12-31StandaloneNumber of employees
Employees127at 2020-12-31dStandaloneNumber of employees
Employees107at 2019-12-31dStandaloneNumber of employees
Employees90at 2018-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 1
SegmentItemPeriodValue
Research And Development Manufacturing And Sales Of Pharmaceuticals Etc And Related Businessreportable segmentemployeesat 2022-12-31122 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,061
ItemContextValueUnit
Net assetsPrior1YearInstant_NonConsolidatedMember6745672000JPY
Cumulative effects of changes in accounting policiesPrior1YearInstant_NonConsolidatedMember_ShareholdersEquityMember-92822000JPY
Cumulative effects of changes in accounting policiesPrior1YearInstant_NonConsolidatedMember-92822000JPY
Restated balancePrior1YearInstant_NonConsolidatedMember_ShareholdersEquityMember6133750000JPY
Restated balancePrior1YearInstant_NonConsolidatedMember_SubscriptionRightsToSharesMember519099000JPY
Restated balancePrior1YearInstant_NonConsolidatedMember6652850000JPY
Issuance of new sharesCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember662000000JPY
Issuance of new sharesCurrentYearDuration_NonConsolidatedMember662000000JPY
Issuance of new sharesexercise of subscription rights to sharesCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember119662000JPY
Issuance of new sharesexercise of subscription rights to sharesCurrentYearDuration_NonConsolidatedMember119662000JPY
Profit lossCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember1186022000JPY
Profit lossCurrentYearDuration_NonConsolidatedMember1186022000JPY
Purchase of treasury stockCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember-2165000JPY
Purchase of treasury stockCurrentYearDuration_NonConsolidatedMember-2165000JPY
Disposal of treasury stockCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember81000JPY
Disposal of treasury stockCurrentYearDuration_NonConsolidatedMember81000JPY
Net changes of items other than shareholders equityCurrentYearDuration_NonConsolidatedMember_SubscriptionRightsToSharesMember-107426000JPY
Net changes of items other than shareholders equityCurrentYearDuration_NonConsolidatedMember-107426000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember1965601000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_SubscriptionRightsToSharesMember-107426000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember1858175000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_ShareholdersEquityMember8099352000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_SubscriptionRightsToSharesMember411672000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember8511025000JPY
Directors compensations sgaPrior1YearDuration_NonConsolidatedMember119643000JPY
Directors compensations sgaCurrentYearDuration_NonConsolidatedMember122418000JPY
Payroll and allowances sgaPrior1YearDuration_NonConsolidatedMember453632000JPY
Payroll and allowances sgaCurrentYearDuration_NonConsolidatedMember461895000JPY
Retirement benefit expenses sgaPrior1YearDuration_NonConsolidatedMember853000JPY
Retirement benefit expenses sgaCurrentYearDuration_NonConsolidatedMember699000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember1736126000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember2546227000JPY
Depreciation sgaPrior1YearDuration_NonConsolidatedMember68737000JPY
Depreciation sgaCurrentYearDuration_NonConsolidatedMember72015000JPY
Compensations sgaPrior1YearDuration_NonConsolidatedMember38318000JPY
Compensations sgaCurrentYearDuration_NonConsolidatedMember103433000JPY
Promotion expenses sgaPrior1YearDuration_NonConsolidatedMember1642559000JPY
Promotion expenses sgaCurrentYearDuration_NonConsolidatedMember1481789000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-03-23
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第18期 (自 2022年１月１日 至 2022年12月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)シンバイオ製薬株式会社
Company name in english cover pageFilingDateInstantSymBio Pharmaceuticals Limited
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長兼CEO 吉田 文紀
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門三丁目２番２号
Telephone number address of registered headquarter cover pageFilingDateInstant03(5472)1125
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)財務経理部長 　畔栁　隆次
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門三丁目２番２号

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 17 of 17 passed
balance sheet identityconsolidated 2022-12-31pass
balance sheet identitynon_consolidated 2021-12-31pass rounding
balance sheet identitynon_consolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2020-12-31pass
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-01-01/2022-12-31pass
statement vs summary · revenuenon_consolidated 2021-01-01/2021-12-31pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsnon_consolidated 2021-12-31pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass